The vascular ectonucleotidase ENTPD1 is a novel renoprotective factor in diabetic nephropathy

Diabetes

Volumn 56, Issue 9, 2007, Pages 2371-2379

  Friedman, David J ^a,d   Rennke, Helmut G ^b   Csizmadia, Eva ^c   Enjyoji, Keiichi ^a   Robson, Simon C ^a,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; STREPTOZOCIN; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; FIBRIN DEPOSITION; GLOMERULOSCLEROSIS; IN VITRO STUDY; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RENAL PROTECTION; UPREGULATION; WILD TYPE;

ANIMALS; ANTIGENS, CD; APYRASE; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; GLOMERULAR MESANGIUM; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; SERUM ALBUMIN; STREPTOZOCIN;

EID: 34548415859     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1593     Document Type: Article

References (45)

1. National Institute of Diabetes and Digestive and Kidney Disease: 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 2004
2. Locatelli F, Pozzoni P, Del Vecchio L: Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 15 (Suppl. 1):S25-S29, 2004
3. Freedman BI, Soucie JM, McClellan WM: Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol 8:1942-1945, 1997
4. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165, 1989
5. Satko SG, Freedman BI, Moossavi S: Genetic factors in end-stage renal disease. Kidney Int Suppl 94:S46-S49, 2005
6. Sevigny J, Sundberg C, Braun N, Guckelberger O, Csizmadia E, Qawi I, Imai M, Zimmermann H, Robson SC: Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 99:2801-2809, 2002
7. Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, Beaudoin AR, Bach FH, Robson SC: Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271:33116-33122, 1996
8. Zimmermann HBN, Heine P, Kohring K, Marxen M, Sevigny J, Robson SC: Ecto-ATPases and Related Nucleotidases. Maastrict, the Netherlands, Shaker, 2000
9. Jacobson KA, Mamedova L, Joshi BV, Besada P, Costanzi S: Molecular recognition at adenine nucleotide (P2) receptors in platelets. Semin Thromb Hemost 31:205-216, 2005
10. Kaczmarek E, Erb L, Koziak K, Jarzyna R, Wink MR, Guckelberger O, Blusztajn JK, Trinkaus-Randall V, Weisman GA, Robson SC: Modulation of endothelial cell migration by extracellular nucleotides: involvement of focal adhesion kinase and phosphatidylinositol 3-kinase-mediated pathways. Thromb Haemost 93:735-742, 2005
11. Burnstock G: Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 22:364 -373, 2002
12. Harada H, Chan CM, Loesch A, Unwin R, Burnstock G: Induction of proliferation and apoptotic cell death via P2Y and P2X receptors, respectively, in rat glomerular mesangial cells. Kidney Int 57:949-958, 2000
13. Kishore BK, Isaac J, Fausther M, Tripp SR, Shi H, Gill PS, Braun N, Zimmermann H, Sevigny J, Robson SC: Expression of NTPDase1 and NTPDase2 in murine kidney: relevance to regulation of P2 receptor signaling. Am J Physiol Renal Physiol 288:F1032-F1043, 2005
14. Candinas D, Koyamada N, Miyatake T, Siegel J, Hancock WW, Bach FH, Robson SC: Loss of rat glomerular ATP diphosphohydrolase activity during reperfusion injury is associated with oxidative stress reactions. Thromb Haemost 76:807-812, 1996
15. Robson SC, Kaczmarek E, Siegel JB, Candinas D, Koziak K, Millan M, Hancock WW, Bach FH: Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 185:153-163, 1997
16. Imai M, Takigami K, Guckelberger O, Enjyoji K, Smith RN, Lin Y, Csizmadia E, Sevigny J, Rosenberg RD, Bach FH, Robson SC: Modulation of nucleoside [correction of nucleotide] triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection. Mol Med 5:743-752, 1999
17. Koyamada N, Miyatake T, Candinas D, Hechenleitner P, Siegel J, Hancock WW, Bach FH, Robson SC: Apyrase administration prolongs discordant xenograft survival. Transplantation 62:1739-1743, 1996
18. Canani LH, Ng DP, Smiles A, Rogus JJ, Warram JH, Krolewski AS: Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes. Diabetes 51:1188-1193, 2002
19. De Cosmo S, Trevisan R, Dalla Vestra M, Vedovato M, Argiolas A, Solini A, Saller A, Damone F, Tiengo A, Trischitta V, Fioretto P: PC-1 amino acid variant Q121 is associated with a lower glomerular filtration rate in type 2 diabetic patients with abnormal albumin excretion rates. Diabetes Care 26:2898-2902, 2003
20. Awad AS, Huang L, Ye H, Duong ET, Bolton WK, Linden J, Okusa MD: Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol 290:F828-F837, 2006
21. Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS 2nd, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD: Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5:1010-1017, 1999
22. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K: Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 31:217-233, 2005
23. Beckstead JH: A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. J Histochem Cytochem 42:1127-1134, 1994
24. Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K: Mouse models of diabetic nephropathy. J Am Soc Nephrol 16:27-45, 2005
25. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA: Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67:1297-1307, 2005
26. Lyon CJ, Hsueh WA: Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 115 (Suppl. 8A):62S-68S, 2003
27. Bouchie JL, Chen HC, Carney R, Bagot JC, Wilden PA, Feener EP: P2Y receptor regulation of PAI-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20:866-873, 2000
28. MacKay K, Striker LJ, Elliot S, Pinkert CA, Brinster RL, Striker GE: Glomerular epithelial, mesangial, and endothelial cell lines from transgenic mice. Kidney Int 33:677-684, 1988
29. von Kugelgen I, Wetter A: Molecular pharmacology of P2Y-receptors. Naunyn Schmiedebergs Arch Pharmacol 362:310-323, 2000
30. Schena FP, Gesualdo L: Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 16 (Suppl. 1):S30-S33, 2005
31. Lazarowski ER, Watt WC, Stutts MJ, Boucher RC, Harden TK: Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol 116:1619-1627, 1995
32. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69:73-80, 2006
33. Bodin P, Bailey D, Burnstock G: Increased flow-induced ATP release from isolated vascular endothelial cells but not smooth muscle cells. Br J Pharmacol 103:1203-1205, 1991
34. Hechler B, Cattaneo M, Gachet C: The P2 receptors in platelet function. Semin Thromb Hemost 31:150-161, 2005
35. Chizh BA, Illes P: P2X receptors and nociception. Pharmacol Rev 53:553-568, 2001
36. Kishi Y, Ohta S, Kasuya N, Sakita SY, Ashikaga T, Isobe M: Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells. J Hypertens 21:1347-1353, 2003
37. Navarro JF, Mora C: Role of inflammation in diabetic complications. Nephrol Dial Transplant 20:2601-2604, 2005
38. Kluth DC, Erwig LP, Rees AJ: Multiple facets of macrophages in renal injury. Kidney Int 66:542-557, 2004
39. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K: Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58:684-690, 2000
40. Schwiebert EM, Kishore BK: Extracellular nucleotide signaling along the renal epithelium. Am J Physiol Renal Physiol 280:F945-F963, 2001
41. Schulze-Lohoff E, Zanner S, Ogilvie A, Sterzel RB: Extracellular ATP stimulates proliferation of cultured mesangial cells via P2-purinergic receptors. Am J Physiol 263:F374-F383, 1992
42. Rivera I, Zhang S, Fuller BS, Edwards B, Seki T, Wang MH, Marrerro MB, Inscho EW: P2 receptor regulation of [Ca2+]i in cultured mouse mesangial cells. Am J Physiol Renal Physiol 292:F1380-F1389, 2007
43. Erb L, Liao Z, Seye CI, Weisman GA: P2 receptors: intracellular signaling. Pflugers Arch 452:552-562, 2006
44. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW: The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28:2686-2690, 2005
45. Breyer MD, Bottinger E, Brosius FC, Coffman TM, Fogo A, Harris RC, Heilig CW, Sharma K: Diabetic nephropathy: of mice and men. Adv Chronic Kidney Dis 12:128-145, 2005